Favipiravir Combined With Tocilizumab

PreclinicalMonoclonal antibody

Favipiravir Combined With Tocilizumab is one of 5 small molecule programs targeting Tocilizumab. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TocilizumabUnknown status

TocilizumabPreclinical

Unknown status

Competition

Competitive Landscape

4 competitors in Tocilizumab

#DrugCompanyPhaseTrials

Actemra

CCelltrion

Approved

36 2

Cytoxan

BBaxter Healthcare Corporation

Phase 2

2 3

Xeljanz

PPrism Pharmaceuticals

Phase 2

1 4

Complarate

AAO GENERIUM

Phase 1

2 5

Favipiravir Combined With Tocilizumab

PPeking University First Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tocilizumab1 trial

Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019

Unknown status·PPeking University First Hospital·N/A·NCT04310228·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Favipiravir Combined With Tocilizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Favipiravir Combined With Tocilizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Favipiravir Combined With Tocilizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University First Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: PPeking University First Hospital

Favipiravir Combined With Tocilizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tocilizumab1 trial

References

Drug Info

Quick Facts

Related News